Healthcare VC Interview Pressure Test
This conversation was generated using Cook'd AI's career assistant and reviewed by Fallon Han from our editorial team for accuracy.
I am an MBA student in the US on F-1 status, and I want a realistic practice interview for healthcare venture capital. I keep getting stuck when people ask about regulatory barriers and reimbursement. Can you press me on the industry knowledge I should know?
Absolutely. I will interview you as if you are meeting with a healthcare VC partner. I will expect you to know the basics of FDA regulation, CMS reimbursement, provider adoption, and why some health tech startups have durable moats while others do not. First question: pick one healthcare startup category, like digital therapeutics, diagnostics, or care navigation, and explain the biggest regulatory barrier and why it matters for commercialization.
I would choose digital therapeutics. The biggest barrier is whether the product needs FDA clearance or approval, because that affects timeline, claims, and investor risk. If the product makes treatment claims or changes clinical decision making, it can face more scrutiny, which slows launch and raises costs.
Good start, but be more precise. In a real interview, I would ask what specific regulatory pathway you are thinking of and how that changes the go to market plan. Also, do not stop at the FDA. What happens if a product gets cleared but still cannot get paid for by insurers or health systems? Walk me through why reimbursement can be the real bottleneck.
Even if a product is allowed on the market, it may not be widely used without reimbursement. If payers do not cover it, patients may not pay out of pocket and providers may not adopt it. So the company needs evidence of clinical value and cost savings, then has to fit into existing billing codes, contracting, or value based care economics.
Better. Now I want you to connect this to venture investing. If two startups both look strong technically, how would you judge which one has a better moat in healthcare? I am looking for a concrete answer tied to data, workflow, regulation, and distribution, not just a generic network effects answer.
I would favor the startup that is embedded in provider workflow and has proprietary data that improves over time. If it also has regulatory complexity that is hard to replicate, like a validated clinical model or compliance infrastructure, that can strengthen the moat. Distribution matters too, especially if it has a strong partnership with a health system, payer, or EHR platform.
That is the right direction. Final question: imagine a founder says, We have a great product and early pilot results, so reimbursement will follow. How would you challenge that claim in an interview, and what would you want to see before you believe the story?
I would challenge that by saying pilots do not equal scalable payment. I would ask whether the product has a clear reimbursement pathway, who the budget holder is, what the clinical and economic endpoints are, and whether the buyer has a reason to renew after the pilot. I would also want evidence from comparable products, payer feedback, and a realistic sales cycle before I would underwrite the opportunity.